Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers

1441 2012 52 1441-1447 F surgery, effective postsurgical pain management is essential because most patients experience pain that often persists for several days or even weeks. For a wide range of surgical procedures, local anesthetics administered via an epidural injection, peripheral nerve blocks, or local infiltrations are commonly used to provide postoperative analgesia. However, the duration of analgesic action of local anaesthetics is typically less than 12 hours. Bupivacaine is among the most widely used long-acting local anesthetics with its moderate onset and long duration of action demonstrated in preclinical and clinical studies. However, longer acting local anesthetics are known to induce systemic toxicity, mostly in relation to the central nervous system (excitation) and cardiovascular system (depression). The cardiotoxicity of bupivacaine and its effects on the QTc interval have been demonstrated in preclinical studies. Besides its known sodium channel– blocking properties, it has been shown to block calcium and potassium channels. The effects of bupivacaine on human cloned cardiac delayed rectifier potassium channels have been described by Gristwood. Blocking potassium channels can lengthen cardiac action potential, leading to serious arrhythmias. One study in dogs showed that administration of 4 mg/kg bupivacaine significantly prolonged the QTc interval by more than 25%. Cardiovascular effects of bupivacaine were also demonstrated in clinical studies. In one such study, patients were administered 40 mL of bupivacaine 5 mg/mL for scheduled shoulder arthroscopy. A significant prolongation of the PQ interval was seen 125 minutes postapplication of bupivacaine, which remained significantly prolonged until 6 hours postdose. Double-blind crossover studies in healthy human volunteers have demonstrated that a maximum dose of 48 mg bupivacaine (maximum plasma concentration of 2.25 mg/L) significantly increased the QTc interval by 26.9 ms. Another study showed that in subjects receiving more than 75 mg bupivacaine, the maximum increase in the QTc interval was 24 ms (P = .022). EXPAREL, a new formulation of bupivacaine, given as a single injection after surgery, could provide adequate, continuous, and extended pain relief,

[1]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[2]  B. Covino,et al.  Rational Use of Local Anaesthetics , 1984, Drugs.

[3]  Yaning Wang,et al.  Creation of a Knowledge Management System for QT Analyses , 2011, Journal of clinical pharmacology.

[4]  A. Camm,et al.  A Nonparametric Approach to QT Interval Correction for Heart Rate , 2010, Journal of biopharmaceutical statistics.

[5]  D. Tompson,et al.  Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects. , 2008, British journal of clinical pharmacology.

[6]  M. Angst,et al.  Pharmacology of Drugs Formulated with DepoFoam™ , 2006, Clinical pharmacokinetics.

[7]  A. Camm,et al.  Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. , 2005, Heart rhythm.

[8]  Colette Strnadova The Assessment of QT/QTc Interval Prolongation in Clinical Trials: A Regulatory Perspective , 2005 .

[9]  M. Wujtewicz,et al.  Influence of Spinal Anesthesia on Corrected QT Interval , 2005, Regional Anesthesia & Pain Medicine.

[10]  A. Borgeat,et al.  Interscalene Brachial Plexus Anesthesia With Ropivacaine 5 mg/mL and Bupivacaine 5 mg/mL: Effects on Electrocardiogram , 2004, Regional Anesthesia & Pain Medicine.

[11]  Joel Morganroth,et al.  A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. , 2004, Journal of electrocardiology.

[12]  R. Gristwood Cardiac and CNS toxicity of levobupivacaine: strengths of evidence for advantage over bupivacaine. , 2002, Drug safety.

[13]  D. Bloomfield,et al.  The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Step 5 NOTE FOR GUIDANCE ON THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS (CHMP/ICH/2/04) TRANSMISSION TO CHMP , 2002 .

[14]  A. Markham,et al.  Levobupivacaine , 2000, Drugs.

[15]  R. Gristwood,et al.  A comparison of the cardiovascular effects of levobupivacaine and rac-bupivacaine following intravenous administration to healthy volunteers. , 2002, British journal of clinical pharmacology.

[16]  B. Veering,et al.  Cardiovascular and Central Nervous System Effects of Intravenous Levobupivacaine and Bupivacaine in Sheep , 1998, Anesthesia and analgesia.

[17]  K.,et al.  Central nervous and cardiovascular effects of i.v. infusions of ropivacaine, bupivacaine and placebo in volunteers. , 1997, British journal of anaesthesia.

[18]  J. Eledjam,et al.  Succinylcholine does not worsen bupivacaine-induced cardiotoxicity in pentobarbital-anaesthetized dogs , 1992, Canadian journal of anaesthesia = Journal canadien d'anesthesie.